These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35388442)

  • 21. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.
    Subiela JD; Gomis Sellés E; Maldonado A; Lopez Campos F; Aumatell Ovide J; Ajuria Illarramendi O; González-Padilla DA; Gajate P; Ortega Polledo LE; Alonso Y Gregorio S; Guerrero-Ramos F; Gómez Dos Santos V; Rodríguez-Patrón R; Calais J; Kishan AU; Burgos Revilla FJ; Couñago F
    Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e676-e688. PubMed ID: 37802722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Performance and Clinical Impact of
    Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
    J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
    Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
    Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.
    van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L
    BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distribution of prostate cancer recurrences on gallium-68 prostate-specific membrane antigen (
    Huits TH; Luiting HB; van der Poel HG; Nandurkar R; Donswijk M; Schaake E; Vogel W; Roobol MJ; Wit E; Stricker P; Emmett L; van Leeuwen PJ
    BJU Int; 2020 Jun; 125(6):876-883. PubMed ID: 32181951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.
    Luiting HB; van Leeuwen PJ; Busstra MB; Brabander T; van der Poel HG; Donswijk ML; Vis AN; Emmett L; Stricker PD; Roobol MJ
    BJU Int; 2020 Feb; 125(2):206-214. PubMed ID: 31680398
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
    Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [
    Perry E; Talwar A; Taubman K; Ng M; Wong LM; Booth R; Sutherland TR
    Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2038-2046. PubMed ID: 33399941
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Ga-68-PSMA PET/CT on management in prostate cancer patients with very early biochemical recurrence after radical prostatectomy.
    Bashir U; Tree A; Mayer E; Levine D; Parker C; Dearnaley D; Oyen WJG
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):901-907. PubMed ID: 30617554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Site-specific relapse patterns of patients with biochemical recurrence following radical prostatectomy assessed by
    Devos G; Witters M; Moris L; Van den Broeck T; Berghen C; Devlies W; De Meerleer G; Goffin K; Jentjens S; Albersen M; Van Poppel H; Everaerts W; Joniau S
    World J Urol; 2021 Feb; 39(2):399-406. PubMed ID: 32417995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3-Year Freedom from Progression After
    Emmett L; Tang R; Nandurkar R; Hruby G; Roach P; Watts JA; Cusick T; Kneebone A; Ho B; Chan L; van Leeuwen PJ; Scheltema MJ; Nguyen A; Yin C; Scott A; Tang C; McCarthy M; Fullard K; Roberts M; Francis R; Stricker P
    J Nucl Med; 2020 Jun; 61(6):866-872. PubMed ID: 31676727
    [No Abstract]   [Full Text] [Related]  

  • 34. The Diagnostic Performance of 18F-PSMA-1007 PET/CT in Prostate Cancer Patients with Early Recurrence after Definitive Therapy with a PSA <10 ng/ml.
    Lengana T; Lawal I; Janse Van Rensburg C; Mokoala K; Moshokoa E; Mazibuko S; Van de Wiele C; Maes A; Vorster M; Sathekge MM
    Nuklearmedizin; 2022 Apr; 61(2):120-129. PubMed ID: 35421900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiphasic
    Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
    J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection Efficacy of Hybrid
    Einspieler I; Rauscher I; Düwel C; Krönke M; Rischpler C; Habl G; Dewes S; Ott A; Wester HJ; Schwaiger M; Maurer T; Eiber M
    J Nucl Med; 2017 Jul; 58(7):1081-1087. PubMed ID: 28209912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathological predictors of
    Perry E; Talwar A; Taubman K; Ng M; Wong LM; Sutherland TR
    BJU Int; 2022 Jun; 130 Suppl 1(Suppl 1):28-36. PubMed ID: 35768883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of
    Mena E; Rowe SP; Shih JH; Lindenberg L; Turkbey B; Fourquet A; Lin FI; Adler S; Eclarinal P; McKinney YL; Citrin DE; Dahut W; Wood BJ; Chang R; Levy E; Merino M; Gorin MA; Pomper MG; Pinto PA; Eary JF; Choyke PL; Pienta KJ
    J Nucl Med; 2022 Aug; 63(8):1184-1190. PubMed ID: 34916246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Comprehensive Assessment of
    Abghari-Gerst M; Armstrong WR; Nguyen K; Calais J; Czernin J; Lin D; Jariwala N; Rodnick M; Hope TA; Hearn J; Montgomery JS; Alva A; Reichert ZR; Spratt DE; Johnson TD; Scott PJH; Piert M
    J Nucl Med; 2022 Apr; 63(4):567-572. PubMed ID: 34326126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [
    Vogel MME; Kroeze SGC; Henkenberens C; Schmidt-Hegemann NS; Kirste S; Becker J; Burger IA; Derlin T; Bartenstein P; Mix M; la Fougère C; Eiber M; Christiansen H; Belka C; Grosu AL; Müller AC; Guckenberger M; Combs SE
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2328-2338. PubMed ID: 32179961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.